6:42 pm Takeda Pharma: FDA accepts supplemental New Drug Application for review of Brintellix (vortioxetine) (TKPYY) : Co and H. Lundbeck A/S (HLUYY) announce the FDA has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. Brintellix is currently approved and available in the U.S. for the treatment of MDD in adults. The FDA is expected to take action on this filing by March 28, 2016.

6:18 pm Simon Properties announces sale of $500 mln of 2.50% senior notes due 2020 and $600 mln of 3.50% senior notes due 2025 (SPG) : Combined, the new issues of senior notes have a weighted average term of 7.8 years and a weighted average coupon rate of 3.05%. The Operating Partnership intends to use the net proceeds of this offering to fund the redemption of all $366.6 million outstanding principal amount of its 5.75% notes due 2015, and for general corporate purposes. Citigroup Global Markets Inc., RBC Capital Markets, LLC and UBS Securities LLC are serving as joint book-running managers of the public offering.

5:41 pm Harris & Harris reports June 30, 2015 net asset value of $3.34 per share; Board authorizes $2.5 mln stock repurchase program (TINY) :  

5:32 pm Hertz Global misses by $0.01, reports revs below consensus; Reaffirms $1 bln share buyback; Reaffirms HERC rollout; Reaffirms 2015 guidance (HTZ) : Reports Q2 (Jun) earnings of $0.19 per share, $0.01 worse than the Capital IQ Consensus Estimate of $0.20; revenues fell 4.9% year/year to $2.69 bln vs the $2.71 bln consensus.

• Total U.S. Car Rental revenues were $1,615 million in the second quarter of 2015, down 3% from the second quarter of 2014 as a result of a 2% overall decline in transaction days. This decline was attributable to a decrease in airport rental volume, as well as a decrease in off-airport rental volume due in part to the closure of approximately 200 stores. 
• Total International Car Rental revenues were $556 million in the second quarter of 2015, down 13% from the second quarter of 2014. This decrease was primarily due to the unfavorable year-over-year impact of foreign currency, which reduced revenues by $105 million. 
• Total Worldwide Equipment Rental revenues were $375 million for the second quarter of 2015, down 2% compared with the prior-year period. Excluding the impact of foreign currency, revenue increased $3 million, or 1%. Revenue was negatively affected by accelerating weakness in upstream oil and gas markets during the quarter. 

Reaffirms 2015 Guidance

• Corporate EBITDA in the range of $1.45-1.55 bln
• U.S. RAC Depreciation $295-305
• US RAC Fllet Capacity Growth 0.5-1.5%
• Net non-fleet capex $275-295 mln

Buyback, HERC Rollout

• Hertz Global reaffirmed its commitment to its previously announced $1 billion share repurchase program and outlined its intent to execute consistent with announced year-end 2016 leverage targets, cash flow generation and other actions such as the contemplated sale of Hertz Equipment Rental Corporation operations in France and Spain, and the ultimate spin-off of HERC.
  

5:15 pm Rock Creek Pharma reports Q2 net loss of $0.08 mln vs loss of $12.7 mln in prior year; to withdraw its current US IND submission (RCPI) :

• "In light of the Company's ongoing clinical advances in Europe and the generation of oral phase I safety data, the Company has carefully evaluated its regulatory strategy in the United States. As indicated in a Form 8-K filing on April 2, 2015, the Company has remained on an FDA-imposed clinical hold for an oral phase I safety study. Because the US IND Phase I, first-in-human, single ascending dose PK protocol is essentially encompassed by the ongoing MHRA approved, European Phase I safety trial, which is nearing completion, the Company has decided to withdraw its current US IND submission. The Company believes this strategy will provide a pathway for subsequent clinical and regulatory development in the United States as the Company accumulates human safety and efficacy data in its EU dermatological developmental program."
  
• "Given other advantages of dermatological trial designs and timelines, the Company is formulating Anatabine Citrate for clinical trials of human inflammatory skin diseases. The Company has been unifying its scientific, clinical, regulatory and consultancy resources to plan a Phase IB, proof-of-concept trial with patients diagnosed with mild to moderate psoriasis in Europe, which is expected to commence in the first quarter of 2016."

5:12 pm Payment Data Systems shares to begin trading on Nasdaq tomorrow under symbol PYDSD following uplisting approval, symbol will revert to PYDS on August 20 (PYDS) :  

5:11 pm Omeros beats by $0.15, beats on revs (OMER) : Reports Q2 (Jun) loss of $0.44 per share, $0.15 better than the Capital IQ Consensus Estimate of ($0.59); revenues rose 608.2% year/year to $3.19 mln vs the $2.86 mln consensus. 

• "Our efforts have been successful and, further supported by our patient assistance and commercial copay programs, we expect to make Omidria accessible by all patients across all insurer types, removing any remaining financial impediment to use of Omidria for all who qualify. We expect that success in the U.S. will help us in Europe where the drug was recently approved for commercialization, and we are pursuing our strategy of entering into one or more marketing and distribution partnerships. Through our OMS103 commercialization agreement with Fagron, sales should begin this year, adding to the revenue stream generated by Omidria. OMS721, in a Phase 2 clinical program for aHUS and other TMAs, now has both orphan and Fast Track designations from FDA, is available for compassionate use in Europe, and additional clinical trial data are expected soon."
  

5:09 pm Diplomat Pharmacy to offer AstraZeneca's (AZN) IRESSA, recently approved by the FDA as a first-line therapy for a specific type of metastatic non-small cell lung cancer (DPLO) :  

5:09 pm United Continental reports July operational performance; July 2015 consolidated traffic (revenue passenger miles) increased 2.8% (UAL) : Consolidated capacity (available seat miles) increased 2.4 percent versus July 2014. UAL's July 2015 consolidated load factor increased 0.3 points compared to July 2014.

5:08 pm Spirit Airlines reports that July 2015 traffic was up 32% y/y (SAVE) : Traffic (revenue passenger miles) in July 2015 increased 32.0 percent versus July 2014 on a capacity (available seat miles) increase of 35.8 percent. Load factor for July 2015 was 88.8 percent, a decrease of 2.6 percentage points compared to July 2014. Spirit's preliminary systemwide completion factor for July 2015 was 98.9 percent.

5:05 pm Mindray Medical misses by $0.04, misses on revs (MR) : Reports Q2 (Jun) earnings of $0.42 per share, $0.04 worse than the Capital IQ Consensus Estimate of $0.46; revenues rose 0.7% year/year to $336.8 mln vs the $360.5 mln consensus. 

• Mindray now expects its full year 2015 net revenues to grow by a low-single-digit percentage over its full year 2014 net revenues. 
• Mindray has revised its full year 2015 non-GAAP net income and now expects it to decrease by around 30% over its full year 2014 non-GAAP net income. This revision is due to lower revenue guidance and lower interest income. 
• The company expects its capital expenditure for full year 2015 to be around $150 million.
  

5:03 pm Cohen & Steers announces July preliminary AUM of $52 bln, an increase of $1.8 bln M/M (CNS) : The increase was due to market appreciation of $1.9 billion partially offset by open-end mutual fund net outflows of $24 million

5:02 pm CBIZ announces that it sold its Bethesda, Maryland, financial services practice to Cherry Bekaert LLP effective August 1, 2015; terms not disclosed (CBZ) :  

5:02 pm DGSE announces the resignation of Chairman and CEO James Clem, effective September 15, 2015 (DGSE) : Clem is leaving to pursue other opportunities, and no replacement has been named at this time. Two members of DGSE's Board of Directors, Bruce A. Quinnell and Dennis A. McGill, have also tendered their resignations from the board, effective August 4, 2015 and August 6, 2015, respectively. Quinnell and McGill both leave the board due to personal reasons, unrelated to Mr. Clem's resignation. Co is currently engaged in a search to fill the Chief Executive role, as well as the two independent director seats

5:01 pm Service Corp prices its $300 mln in Senior Notes due 2024 at 5.375% (SCI) : Co will use the net proceeds from this offering to redeem all of its outstanding 6.750% Senior Notes due 2016 and to repay approximately $88 million of outstanding borrowings under its revolving credit facility.

• Co also announced today that it will be issuing a notice for the redemption of approximately $197 million aggregate principal amount of its 6.750% Senior Notes due 2016
  

4:59 pm Stifel Financial misses by $0.01, reports revs in-line (SF) : Reports Q2 (Jun) earnings of $0.71 per share, $0.01 worse than the Capital IQ Consensus Estimate of $0.72; revenues rose 6.7% year/year to $597.8 mln vs the $596.11 mln consensus. 

Brokerage revenues, defined as commissions and principal transactions revenues, were $269.3 million, a 2.1% decrease compared with the second quarter of 2014 and a 4.0% decrease compared with the first quarter of 2015. 

• Global wealth management brokerage revenues were $158.8 million, a 1.1% decrease compared with the second quarter of 2014 and a 0.5% increase compared with the first quarter of 2015.
• Institutional equity brokerage revenues were $58.6 million, a 3.8% decrease compared with the second quarter of 2014 and a 5.3% decrease compared with the first quarter of 2015. 
• Institutional fixed income brokerage revenues were $52.0 million, a 3.2% decrease compared with the second quarter of 2014 and a 14.4% decrease compared with the first quarter of 2015. 

Investment banking revenues were $161.0 million, an 11.2% increase compared with the second quarter of 2014 and a 28.7% increase compared with the first quarter of 2015. 

• Equity capital raising revenues were $55.5 million, a 15.7% decrease compared with the second quarter of 2014 and a 13.3% increase compared with the first quarter of 2015. 
• Fixed income capital raising revenues were $41.9 million, a 124.2% increase compared with the second quarter of 2014 and a 57.0% increase compared with the first quarter of 2015.
• Advisory fee revenues were $63.6 million, a 5.4% increase compared with the second quarter of 2014 and a 28.7% increase compared with the first quarter of 2015.
  

4:58 pm Yodlee beats by $0.01, reports revs in-line -- being acquired by Envestnet (ENV) (YDLE) : Reports Q2 (Jun) net of breakeven, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of ($0.01); revenues rose 22.1% year/year to $26 mln vs the $25.88 mln consensus.

• Envestnet will acquire all of the shares of Yodlee in a cash and stock transaction valued at $18.88 per share, or ~$660 million on a fully-diluted equity value basis. As Yodlee has ~$70 million in cash and cash equivalents, the transaction reflects an enterprise value of approximately $590 million.
  

4:57 pm Axalta Coating Systems announces a 30 mln share secondary offering of common stock, by selling stockholders affiliated with The Carlyle Group (AXTA) :  

4:55 pm Howard Hughes beats single analyst estimates by $0.01, beats on revs (HHC) : Reports Q2 (Jun) earnings of $0.18 per share, $0.01 better than the single analyst estimate of $0.17; revenues fell 0.2% year/year to $209.16 mln vs the $147.96 mln single analyst estimate.

4:55 pm Xerium Tech misses Q2 estimates; lowers FY15 guidance (XRM) :

• Q2 adj. EPS $0.37 vs $0.40 Capital IQ Consensus Estimate; revs $123.1 mln vs $130.55 mln Capital IQ Consensus. 
• Updated full year 2015 guidance to be similar to 2014, reflecting near-term newsprint and graphical grade decline trends and weak euro. Sales growth investment programs remain on track with 8 facilities beginning production or ramping up production capabilities in the second half of 2015 coupled with over 39 new patented products. 
• "During the second quarter of 2015, the machine clothing and rolls sales environment was more challenging than we had anticipated due to customer shutdowns and curtailments... We view this as a temporary dynamic given our multi-year sales growth investments are in the early stages of gaining traction and will increasingly augment our sales growth. We expect the incremental earnings from our sales growth investment programs to more than offset the permanent market declines in graphical paper production. To further increase our profit rates, we are continuing to take costs out of the business. This includes the recent closure of a machine clothing facility in Warwick, Quebec, Canada. The cost structure at this plant was operating at almost twice the level of our low-cost facilities. We still have other facilities with very large cost reduction opportunities."
  

4:55 pm Medley Capital misses by $0.01 (MCC) : Reports Q3 (Jun) net investment income of $0.30 per share, $0.01 worse than the Capital IQ Consensus Estimate of $0.31.

• As of June 30, 2015, the Company had a cash balance of $36.2 million and $181.7 million of debt outstanding under its $346.0 million senior secured revolving credit facility.
  

4:52 pm DTS beats by $0.04, beats on revs; guides FY15 EPS in-line, revs in-line (DTSI) : Reports Q2 (Jun) earnings of $0.34 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus Estimate of $0.30; revenues fell 5.0% year/year to $34.4 mln vs the $33.48 mln consensus. Co issues in-line guidance for FY15, sees EPS of $1.65-1.75, excluding non-recurring items, vs. $1.70 Capital IQ Consensus Estimate; sees FY15 revs of $140-145 mln vs. $151.96 mln Capital IQ Consensus Estimate.

4:50 pm Intl Flavors misses by $0.07, misses on revs (IFF) : Reports Q2 (Jun) earnings of $1.29 per share, $0.07 worse than the Capital IQ Consensus Estimate of $1.36; revenues fell 2.6% year/year to $767.54 mln vs the $776.16 mln consensus.

4:48 pm QTS Realty Trust announces an offering of 2.4 mln shares of its common stock, by a selling stockholder affiliated with General Atlantic LLC (QTS) :  

4:48 pm Organovo misses by $0.01 (ONVO) : Reports Q1 (Jun) loss of ($0.10) per share, $0.01 worse than the Capital IQ Consensus Estimate of loss of ($0.09); revenues rose year/year to $0.31 mln vs the $0.43 mln consensus.

4:44 pm Google announces plans for new operating structure; will create a new company called Alphabet, which will replace Google Inc. as a publicly-traded entity (GOOG) : Co announced that Alphabet Inc. will replace Google Inc. as the publicly-traded entity and all shares of Google will automatically convert into the same number of shares of Alphabet, with all of the same rights. Google will become a wholly-owned subsidiary of Alphabet. Its two classes of shares will continue to trade on Nasdaq as GOOGL and GOOG. CEO Page's statement highlights included:

• "We are creating a new company, called Alphabet. I am really excited to be running Alphabet as CEO with help from my capable partner, Sergey, as President. What is Alphabet? Alphabet is mostly a collection of companies. The largest of which, of course, is Google. In addition, with this new structure we plan to implement segment reporting for our Q4 results, where Google financials will be provided separately than those for the rest of Alphabet businesses as a whole. I should add that we are not intending for this to be a big consumer brand with related products-the whole point is that Alphabet companies should have independence and develop their own brands."

4:41 pm RCI Hospitality reports Q3 EPS of $0.32, ex items, prior year $0.30; Revenues increased 7% y/y to $35.8 mln (RICK) : "Company on track for a solid FY15 and another year of growth in FY16".

4:40 pm Acadia Healthcare announces a 5,033,230 mln share secondary offering of its common stock, by selling shareholders affiliated with Waud Capital Partners and Bain Capital Investors (ACHC) :  

4:39 pm Franco-Nevada misses by $0.01, reports revs in-line (FNV) : Reports Q2 (Jun) earnings of $0.15 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus Estimate of $0.16; revenues rose 1.6% year/year to $109.4 mln vs the $110.15 mln consensus.

• Co reported Q2 financial results realizing 83,040 Gold Equivalent Ounces from its mineral assets and $10.3 million in revenue from its oil & gas assets. Adjusted EBITDA was $82.2 mln.
• "Our balance sheet remains very liquid with no debt. We see downturns as an opportunity for even better investments. There continues to be many active opportunities and Franco-Nevada has increased its credit facility to $750 million to be better positioned to act on the right ones."

4:38 pm Ocular Therapeutix reports Q2 net loss of $10.0 mln or ($0.45) per share, dual analyst estimate is ($0.33); Reports revenue of $500K, dual analyst estimate $440K (OCUL) :

• Submission of an NDA for DEXTENZA for a post-surgical ocular pain indication expected in the fourth quarter of 2015.
• Initiation of a third Phase 3 clinical trial for DEXTENZA for post-surgical ocular inflammation and pain expected in the fourth quarter of 2015 with modifications to the trial design based on learnings from the previously completed Phase 3 trials, made subsequent to a pre-NDA meeting with the Food and Drug Administration in April 2015. 
• Submission of an NDA supplement for DEXTENZA expected in the second half of 2016.
• DEXTENZA is being investigated for the treatment of allergic conjunctivitis, and has completed enrollment in a Phase 3 clinical trial. Topline efficacy data from the Phase 3 trial is expected in the fourth quarter of 2015.
• DEXTENZA is also being investigated for the treatment of inflammatory dry eye disease and is in an exploratory Phase 2 clinical trial which is now fully enrolled, with topline efficacy data expected in the fourth quarter of 2015.
• The Company's OTX-TP product candidate for the treatment of glaucoma and ocular hypertension is being evaluated in a Phase 2b clinical trial at multiple sites in the United States. Enrollment is now closed and the company expects to report topline efficacy data in the fourth quarter of 2015.
  

4:37 pm Biocept reports Q2 results (BIOC) :

• Q2 EPS ($0.22) vs ($0.23) Capital IQ Consensus Estimate; revs +305% to $0.77 mln vs $0.60 mln Capital IQ single est.
• "Total sample volume, which includes commercial, development and research assays, grew by 46% to 525 during the second quarter of 2015 from 359 during the first quarter of 2015. We also increased the number of biomarkers tested per sample, which is a direct result of the expansion of our portfolio of commercially available biomarkers. A change in CPT codes early this year, however, caused a delay in reimbursement payments, which impacted quarterly revenues. We believe that we have resolved the reimbursement issue and expect to receive additional revenues from resubmitted claims beginning in the third quarter."
  

4:36 pm RGS Energy reports Q2 EPS of $0.28/share vs. a loss of ($9.27) in the prior year's quarter, which included items; revenue fell 25% to $14.7 mln (RGSE) :

• Solar system installations on homes and small businesses decreased 35.2% to 702 installations in the period from 1,084 installations in the same year-ago period.
• Gross margin for the residential segment was 15.2% in the second quarter of 2015, which increased from 10.3% in the previous quarter and declined from 22.0% in the second quarter of 2014.
• The sequential increase primarily reflects the gross margin percentage increasing whenever there is an increase in revenue as there is a fixed cost element in the cost of goods sold.
• The year-over-year decline reflects residential segment revenue declining by 30% and an approximate three-fold increase in customer cancellations. The customer cancellations arose from the company's previous inability to make installations at an appropriate rate.
  

4:36 pm Norwegian Cruise Line announces the launch of a 20 mln share secondary offering, by selling stockholders affiliated with Apollo Global Management (APO) and TPG Global (NCLH) :  

4:35 pm TrovaGene reports Q2 results (TROV) : Co reports Q2 EPS of $-0.41 vs $-0.24 Capital IQ Consensus Estimate; revs -10.7% y/y to $0.05 mln vs $0.1 mln Captial IQ Consensus Estimate.

4:34 pm Kandi Technologies issues a statement clarifying comments made by CEO Xiaoming regarding the company's outlook for EV product sales (KNDI) : Co stated that a mistranslation of the CEO Hu Xiaoming's response to a question has created a misunderstanding regarding the Company's outlook for EV product sales.

• Hu noted that China's government expects the total number of cars on the road in China by 2020 could reach 200 million, and that EV products could make up 2.5% to 3% of that total. Hu's comment was not in reference to Kandi's share of the market.
  

4:33 pm Noranda Aluminum announces on August 7, co received non-compliance notice from NYSE (NOR) :

• The Company has called a special meeting of stockholders to be held on August 24, 2015, at which the stockholders will consider an amendment to the Company's amended and restated certificate of incorporation that would, among other things, provide for a 1-for-7 reverse stock split.
  

4:33 pm Landauer bets Q2 EPS, misses on rev; lowers FY15 guidance (LDR) :

• Q2 adj. EPS $0.48 vs $0.39 Capital IQ Consensus Estimate; revs $35.5 mln vs $37.37 mln Capital IQ Consensus. 
• Co lowers FY15 revs to $150-153 mln from $153-163 mln vs $152.90 mln Capital IQ two est avg; adj. net income to $16-19 from $18-19 mln.
  

4:32 pm Relm Wireless announces it will hold a special meeting of stockholders to vote on the company's reincorporation into Delaware from Nevada (RWC) :  

4:31 pm Franklin Resources announces July AUMs of $854.7 billion, down from $907.9 billion a year ago (BEN) :  

4:31 pm HC2 reports a Q2 loss of ($0.48) vs. a loss of ($0.22) in last year's quarter; revenue rose 39% to $281.0 mln (HCHC) :

• The YoY increase in revenue was primarily driven by the $57.2 million growth of its Telecommunications segment.
• During the quarter, its Telecommunications segment increase resulted from PTGi ICS's successful overhaul of their global sales team and the expansion into Latin America and other emerging markets.
  

4:30 pm PC-TEL announces Board authorization for the repurchase of 1.3 mln common stock shares (PCTI) : The co. announced that the PCTEL Board of Directors authorized the re-purchase of an additional 1.3 mln shares of its common stock. In 2014 the company announced a buyback of up to five (5) percent of the company's outstanding shares, which is nearing completion. This past April, the Board authorized an additional 500K share stock buyback

4:30 pm OncoMed Pharma misses by $0.05, misses on revs (OMED) :

• Reports Q2 (Jun) loss of $0.72 per share, $0.05 worse than the Capital IQ Consensus Estimate of ($0.67); revenues fell 92.2% year/year to $4.7 mln vs the $12.26 mln consensus. 
  
• Co reiterates its 2015 guidance: 2015 full-year cash expenses are expected to total $100-$110 million, excluding non-cash stock-based compensation, depreciation, and amortization expenses; co projects a 2015 year-end cash, cash equivalents and short-term investments balance of over $120 million, before considering the receipt of any potential collaboration milestones; co could receive more than $150 million in milestone and option payments from partners during 2015 and 2016.
  

4:29 pm Ambac reports Q2 (Jun) results (AMBC) : Reports Q2 (Jun) earnings of $5.70 per share, may not be comparable to the Capital IQ Consensus Estimate of $1.13. 

• Net income in the second quarter of 2015 was $282.7 million, or $6.05 per diluted share, compared to $214.7 million, or $4.57 per diluted share, in the first quarter of 2015. 
• Operating earnings in the second quarter of 2015 were $266.0 million, or $5.70 per diluted share, compared to $247.6 million, or $5.27 per diluted share in the first quarter of 2015. 
• For the second quarter of 2015, net premiums earned were $60.9 million, as compared to $65.7 million in the first quarter of 2015, including accelerations of $13.7 million and $22.9 million, respectively.
• Net investment income for the second quarter of 2015 was $64.8 million, as compared to $73.0 million for the first quarter of 2015. 
• Net investment income for the second quarter of 2015 was lower than first quarter primarily as a result of trading portfolio performance.
  

4:28 pm Hibbett Sporting sees Q2 below consensus (HIBB) :

• Co sees Q2 EPS $0.26-0.28 vs $0.35 Capital IQ Consensus Estimate; revs +2.8% to $199 mln vs $209.31 mln Capital IQ Consensus; comps -1.1%
• "For the second quarter, comparable store sales were softer than expected. While we anticipated slower sales due to 10 states delaying their tax-free weekend by one week (from the last weekend in fiscal July in the prior year to the first week of fiscal August this year), there also was underlying business softness. Details about sales trends in early August and our future outlook will be discussed when we report full second quarter results on August 21, 2015."
  

4:27 pm Envestnet beats by $0.01, reports revs in-line (ENV) :

• Reports Q2 (Jun) earnings of $0.24 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.23; revenues rose 21.1% year/year to $102.7 mln vs the $101.99 mln consensus. 
  
• "During the second quarter, Envestnet onboarded $46 billion in new assets from conversions, reflecting strong demand for our unified offerings from large institutions and registered investment advisors. We believe Envestnet remains well-positioned to deliver meaningful organic growth, and to accelerate that growth through strategic activity, such as our merger with Yodlee (YDLE), announced today." 
  

4:26 pm TubeMogul beats by $0.05, beats on revs; guides Q3 revs above consensus; raises FY15 rev guidance above consensus (TUBE) : Reports Q2 (Jun) loss of $0.04 per share, $0.05 better than the Capital IQ Consensus Estimate of ($0.09); revenues rose 58.2% year/year to $45.44 mln vs the $39.07 mln consensus.

• Co issues upside guidance for Q3, sees Q3 revs of $39-41 mln vs. $36.65 mln Capital IQ Consensus Estimate. sees Total Spend in the range of $94 million to $96 million, gross profit in the range of $26 million to $28 million.
• Co issues upside guidance for FY15, sees FY15 revs of $164-170 mln vs. $154.08 mln Capital IQ Consensus Estimate (vs. prior guidance of $149-157 mln). Sees total Spend in the range of $395 million to $401 million, gross profit in the range of $111 million to $117 million
  

4:25 pm ZIOPHARM beats by $0.21, misses on revs (ZIOP) :

• Reports Q2 (Jun) loss of $0.11 per share, $0.21 better than the Capital IQ Consensus Estimate of ($0.32); revenues rose 36.0% year/year to $0.27 mln vs the $1.65 mln consensus. 
  
• "ZIOPHARM continues to make important headway, both in the lab and clinic, in the development of our novel gene and adoptive cell therapy programs and technologies. This includes advancement of several chimeric antigen receptor (CAR) and T-cell receptor (:TCR) candidates toward the clinic, evolution of the Sleeping Beauty non-viral gene transfer platform, integration of RheoSwitch technology into various adoptive cell therapies and clinical strategies for controlled delivery of IL-12 using adenovirus. Working with Intrexon (XON) and our other partners, we look forward to advancing these cancer immunotherapies, and to presenting early data from across these platforms prior to the end of this year."
  

4:25 pm Black Diamond beats by $0.12, misses on revs; reaffirms guidance (BDE) : Reports Q2 (Jun) earnings of $0.01 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus Estimate of ($0.11); revenues rose 2.0% year/year to $35.1 mln vs the $36.46 mln consensus. The increase in revenue was driven by growth in Black Diamond apparel and the continued rollout of POC's cycling products, including its new spring 2015 "Race Day" line and expanded assortment of eyewear. Excluding the impact of foreign exchange, sales grew 7%.

Outlook:

• Black Diamond's guidance for fiscal 2015 remains on track with sales expected to increase 11% on a constant currency basis. Also on a constant currency basis, the Company expects gross margin in fiscal year 2015 to be ~40%.
  

4:24 pm Shake Shack announces secondary offering of 4 mln shares by a selling shareholder (SHAK) : J.P. Morgan Securities LLC is acting as sole lead book-running manager in the proposed offering. Morgan Stanley & Co. LLC, Barclays Capital Inc., Goldman, Sachs & Co., Jefferies LLC, William Blair & Company, L.L.C. and Stifel are acting as book-running managers in the proposed offering.

4:24 pm ExOne misses by $0.24, misses on revs; reaffirms FY15 revs guidance; lowers margin guidance (XONE) :

• Reports Q2 (Jun) loss of $0.48 per share, $0.24 worse than the Capital IQ Consensus Estimate of ($0.24); revenues fell 24.1% year/year to $8.5 mln vs the $11.09 mln consensus. Non-machine revenue grew 16% to $6.1 million, representing 26% growth excluding the effects of changes in foreign currency exchange rates. Consolidated sales in the 2015 second quarter were unfavorably impacted by ~$0.6 million, or 5%, due to changes in foreign currency exchange rates compared with the 2014 second quarter.
• Co reaffirms guidance for FY15, sees FY15 revs of $58-66 mln vs. $58.71 mln Capital IQ Consensus; subject to customer requirements impacting revenue recognition. 
• Gross margin now expected to be between 30% and 34% (from prior guidance range of 36% to 40%), excluding anticipated non-recurring costs estimated at $0.5 million to $1.0 million to complete facility integrations; revision reflects significant under absorption of overhead costs in the first half of 2015.

4:23 pm Paragon Offshore issues an August Fleet Status Report (PGN) : See Report

4:23 pm PTC proposes to offer $125 million in aggregate principal amount of its convertible senior notes due 2022 (PTCT) : PTC intends to use the net proceeds of the offering for working capital and other general corporate purposes, including to fund the development of its commercial infrastructure and its commercial launch of Translarna, to fund the clinical development of and, subject to favorable clinical results, seek full marketing approval for Translarna for the treatment of nmDMD and nmCF, and to fund the research and development of Translarna for additional indications.

4:23 pm Snyder's-Lance beats by $0.01, reports revs in-line; reaffirms FY15 EPS guidance, revs guidance (LNCE) : Reports Q2 (Jun) earnings of $0.27 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus Estimate of $0.26; revenues rose 8.0% year/year to $431.4 mln vs the $430.14 mln consensus.

• Co reaffirms guidance for FY15, sees EPS of $1.11-1.19, excluding non-recurring items, vs. $1.15 Capital IQ Consensus Estimate; sees FY15 revs of $1.69-1.72 bln vs. $1.71 bln Capital IQ Consensus Estimate.
  

4:22 pm Resolute Energy misses by $3.35, misses on revs (REN) :

• Reports Q2 (Jun) loss of $3.46 per share, $3.35 worse than the Capital IQ Consensus Estimate of ($0.11); revenues fell 45.3% year/year to $48.4 mln vs the $52.13 mln consensus. 
  
• "The second quarter of 2015 was strong for Resolute, and notable for many reasons. Average daily production increased to a record quarterly level, even as we stood-down all drilling activity. Higher production volumes, combined with aggressive cost control and advantageous hedge positions enabled the Company to hold Adjusted EBITDA flat as compared to the prior year period, despite revenue per barrel of oil equivalent ("Boe") that was 50 percent lower than that received in the comparable prior year period. Our cost control efforts yielded exceptional results, as we reduced our quarterly lease operating expenses 40 percent to $15.64 per Boe and cash-based general and administrative expense 31 percent to $3.87 per Boe as compared to the prior year period. Both the lease operating and general and administrative results are better than our public guidance..."
  

4:22 pm Rediff.com India to apply to have its ADRs, presently listed on the Nasdaq Global Market, moved to the Nasdaq Capital Market (REDF) :  

4:21 pm Novavax beats by $0.01, beats on revs (NVAX) : Reports Q2 (Jun) loss of $0.08 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.09); revenues rose 69.5% year/year to $14 mln vs the $9.9 mln consensus.

• "Given the positive top-line Phase 2 data reported today, we look forward to discussions with the regulatory authorities and the opportunity to pursue our goal to initiate a Phase 3 clinical trial of our RSV F Vaccine in older adults later this year."
• 2015 Anticipated Events
• Announcement of safety and immunogenicity data from the RSV F Vaccine Phase 2 trial to protect infants via maternal immunization; and
• Initiation of a Phase 3 trial of the RSV F Vaccine in older adults as early as the fourth quarter.
• As of June 30, 2015, the company had $314.9 million in cash and cash equivalents and marketable securities compared to $168.1 million as of December 31, 2014.
  

4:21 pm Rentrak beats by $0.02, misses on revs (RENT) : Reports Q1 (Jun) earnings of $0.01 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus Estimate of ($0.01); revenues rose 23.3% year/year to $27.5 mln vs the $30.1 mln consensus. 

FY16 Outlook

• Total company revenue growth of 36 percent to 39 percent.
• TV Everywhere revenue growth of 55 percent to 65 percent.
• Accelerating Movies Everywhere growth in the second half of fiscal 2016 related to anticipated contract renewal increases from large domestic studios. The product line will continue to be affected by foreign exchange movements. 
• Adjusted EBITDA before acquisition and reorganization costs of $22.7 million to $25.9 million, or 16 percent to 18 percent of revenues. 
• Longer-term adjusted EBITDA return on revenue target of 35%. 
  

4:21 pm Myers Industries announces that CEO John Orr has established a Rule 10b5-1 trading plan (MYE) :  

4:20 pm McDermott beats by $0.09, beats on revs; guides FY15 revs in-line (MDR) :

• Reports Q2 (Jun) earnings of $0.04 per share, $0.09 better than the Capital IQ Consensus Estimate of ($0.05); revenues rose 119.8% year/year to $1.05 bln vs the $0.81 bln consensus. 
  
• Co issues in-line guidance for FY15, sees FY15 revs of $3.0-3.3 bln, down from prior guidance of $3.3-3.6 bln and vs. the $3.11 bln Capital IQ Consensus Estimate.
  

4:20 pm Portfolio Recovery Assoc. misses by $0.09, misses on revs (PRAA) : Reports Q2 (Jun) earnings of $1.06 per share, $0.09 worse than the Capital IQ Consensus Estimate of $1.15; revenues rose 20.2% year/year to $237.2 mln vs the $246.92 mln consensus.

4:19 pm Hub Group announces the resignation of President and COO Mark Yeager (HUBG) :

• David P. Yeager, Hub's Chairman and Chief Executive Officer, will be assuming Mark's responsibilities on an interim basis while the Company selects a replacement.
  

4:18 pm Bright Horizons announces a secondary offering of 3 mln common stock shares (BFAM) : The co. announced that certain of its stockholders intend to offer for sale 3 mln shares of its common stock pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission, of which the co. intends to repurchase from the underwriter 700,000 shares of common stock. The Selling Stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company. The Company's per-share purchase price for the repurchased shares will be the same as the per-share purchase price payable by the underwriter to the Selling Stockholders. The Company intends to fund the share repurchase with cash on hand.

4:18 pm Profire Energy beats by $0.01, beats on revs; reaffirms FY16 revs guidance, in-line (PFIE) : Reports Q1 (Jun) loss of $0.01 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.02); revenues fell 47.5% year/year to $6.88 mln vs the $6.16 mln consensus.

• Total revenues for the quarter of $6.9 million reflected a decrease of 48%, compared to the comparable period last year.
• This decrease was principally attributable to the reduced purchasing from companies in the oil and gas industry stemming from budget constraints derived from a drastic decline in the underlying commodity prices year over year
• Though the Company expects the difficult industry environment to continue for some time, it is focusing resources in geographic areas that we believe will produce the highest level of total revenues and return on investment, while also focusing on initiatives that might help reduce its long-term exposure to the industry's volatility.
• Co reaffirms guidance for FY16, sees FY16 revs of $25-30 mln vs. $27.88 mln Capital IQ Consensus Estimate.
  

4:18 pm Halozyme Therapeutics beats by $0.11, beats on revs; Raises FY15 revs above consensus (HALO) : Reports Q2 (Jun) earnings of $0.02 per share, $0.11 better than the Capital IQ Consensus Estimate of ($0.09); revenues rose 135.9% year/year to $43.4 mln vs the $25.77 mln consensus.

• Guidance: Co raises guidance for FY15, sees FY15 revs of $110-$115 mln vs. $96.27 mln Capital IQ Consensus Estimate, up from prior guidance of $85-$95. Sees operating expenses to be in the range of $160 million to $170 million, from a prior range of $145 million to $155 million. Sees net cash burn of $20 million to $30 million, from a prior range of $35 to $45 million, with year-end cash balance expected to be $105 million to $115 million.
  
  
• Commentary: "The company raised its revenue projection due to payment received from the AbbVie agreement. Operating expenses are expected to increase primarily due to acceleration of a bulk PH20 manufacturing campaign to fulfill current and future orders, and the building of capabilities related to an expansion of the PEGPH20 clinical program from 2 to 5 trials, including assuring readiness for the global phase 3 study at the end of Q1 2016. Cash burn is expected to decrease due to the inflow of new revenue, partially offset by the increase in planned expenses."

4:18 pm MaxLinear misses by $0.01, reports revs in-line; guides Q3 revs in-line (MXL) : Reports Q2 (Jun) earnings of $0.21 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus Estimate of $0.22; revenues rose 100.1% year/year to $70.8 mln vs the $70.28 mln consensus. Co issues in-line guidance for Q3, sees Q3 revs of $90-94 mln vs. $88.96 mln Capital IQ Consensus Estimate.

4:18 pm Take-Two misses by $0.05, beats on revs; guides Q2 above consensus; reaffirms FY16 guidance, below estimates (TTWO) :

• Reports Q1 (Jun) earnings of $0.31 per share, excluding non-recurring items, $0.05 worse than the Capital IQ Consensus Estimate of $0.36; revenues rose 141.7% year/year to $366.4 mln vs the $350.84 mln consensus. 
• Co issues upside guidance for Q2, sees EPS of $0.05-0.15, excluding non-recurring items, vs. ($0.24) Capital IQ Consensus Estimate; sees Q2 revs of $275-325 mln vs. $171.20 mln Capital IQ Consensus Estimate. 
• Co reaffirms guidance for FY16, sees EPS of $0.75-1.00, excluding non-recurring items, vs. $1.08 Capital IQ Consensus Estimate; sees FY16 revs of $1.3-1.4 bln vs. $1.43 bln Capital IQ Consensus Estimate.
  

4:17 pm Lexington sells the Transamerica Tower in Baltimore, MD for gross proceeds of $121 mln (LXP) :  

4:17 pm Esco Tech reports EPS in-line, misses on revs; guides Q4 EPS below consensus; guides FY15 EPS below consensus (ESE) :

• Reports Q3 (Jun) earnings of $0.41 per share, excluding non-recurring items, in-line with the Capital IQ Consensus Estimate of $0.41; revenues rose 2.8% year/year to $134.2 mln vs the $137.12 mln consensus. 
  
• Co issues downside guidance for Q4, sees EPS of $0.55-0.60 vs. $0.62 Capital IQ Consensus Estimate. Co issues downside guidance for FY15, sees EPS of $1.70-1.75 vs. $1.77 Capital IQ Consensus Estimate.
  

4:17 pm China Mobile Games completes merger, requests that trading in its ADSs to be suspended (CMGE) :  

4:16 pm Model N beats by $0.01, beats on revs; guides Q4 EPS below consensus, revs below consensus (MODN) : Reports Q3 (Jun) loss of $0.08 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.09); revenues rose 22.3% year/year to $23.6 mln vs the $23.24 mln consensus. Adjusted EBITDA was $(1.0) million, compared to $(3.1) million for the third quarter of fiscal 2014.

• Co issues downside guidance for Q4, sees EPS of ($0.09) - ($0.08) vs. ($0.07) Capital IQ Consensus Estimate; sees Q4 revs of $24.6-24.9 mln vs. $25.07 mln Capital IQ Consensus Estimate. 
  

4:16 pm American Public Education misses by $0.03, reports revs in-line; guides Q3 EPS below consensus (APEI) : Reports Q2 (Jun) earnings of $0.42 per share, $0.03 worse than the Capital IQ Consensus Estimate of $0.45; revenues fell 6.1% year/year to $80.3 mln vs the $80.01 mln consensus. Co issues downside guidance for Q3, sees EPS of $0.36-0.41, excluding non-recurring items, vs. $0.45 Capital IQ Consensus Estimate. APEI anticipates consolidated revenues to decrease between approximately 11% and 7% y/y. Net course registrations by new students are expected to decrease between 23% and 19% y/y and total net course registrations are expected to decrease between 8% and 4% y/y. At Hondros College of Nursing, new student enrollment decreased by approximately 6% y/y and total student enrollment increased by approximately 5% y/y in the third quarter of 2015.

4:15 pm Yodlee to be acquired by Envestnet (ENV) for $18.88/share, or ~$660 mln; expected to close in Q4 2015 (shares halted) (YDLE) : Envestnet (ENV) and Yodlee (YDLE) announced that the Boards of Directors of both cos have unanimously approved a definitive agreement under which Envestnet will acquire all of the shares of Yodlee in a cash and stock transaction valued at $18.88 per share, or ~$660 mln on a fully-diluted equity value basis. As Yodlee has ~$70 mln in cash and cash equivalents, the transaction reflects an enterprise value of ~$590 mln.

• Envestnet will acquire Yodlee in a cash-and-stock transaction for $18.88 per share, representing fully-diluted equity value of ~$660 mln. As Yodlee has ~$70 mln in cash and cash equivalents, the transaction reflects an enterprise value of approximately $590 mln. 
• The deal price consists of $10.78 per share in cash and $8.10 per share in Envestnet stock, and is expected to be funded with available balance sheet cash, Envestnet stock, and up to $200 mln in committed debt financing. 
• The stock portion of the consideration will be determined based upon the volume weighted average price per share of Envestnet common stock for the 10 consecutive trading days ending on (and including) the second trading day immediately prior to completion of the transaction, subject to a collar of $39.006 to $47.674 per share. 
• In connection with the definitive agreement, funds affiliated with Warburg Pincus, which collectively own ~26.9% of Yodlee's common stock, have entered into a voting agreement pursuant to which it has committed to support the transaction.
  

4:14 pm Nanosphere misses by $1.12, beats on revs; reaffirms FY15 revs guidance (NSPH) : Reports Q2 (Jun) loss of $2.25 per share, $1.12 worse than the Capital IQ Consensus Estimate of ($1.13); revenues rose 76.8% year/year to $4.72 mln vs the $4.47 mln consensus.

• Co reaffirms guidance for FY15, sees FY15 revs of $18-20 mln vs. $21.41 mln Capital IQ Consensus Estimate.
  
• Cash at June 30, 2015 was $23.9 million, with $3 million of this being restricted cash.
  

4:14 pm Celldex Therapeutics beats by $0.02, beats on revs (CLDX) : Reports Q2 (Jun) loss of $0.33 per share, $0.02 better than the Capital IQ Consensus Estimate of ($0.35); revenues rose 267.9% year/year to $2.18 mln vs the $0.53 mln consensus.

• "At ASCO in June, we presented data from the Phase 2 ReACT study, which achieved the primary endpoint of progression-free survival at six months and, most importantly, demonstrated a survival benefit for patients on the RINTEGA arm. We continue to follow these patients and look forward to presenting data on the emerging long-term survival benefit later this year. The Phase 3 ACT IV study continues to progress as planned, and we look forward to the second interim analysis in late 2015/early 2016."
  

4:13 pm CareDx misses by $0.09, misses on revs; reaffirms FY15 revs guidance (CDNA) : Reports Q2 (Jun) loss of $0.27 per share, $0.09 worse than the Capital IQ Consensus Estimate of ($0.18); revenues rose 4.9% year/year to $7.04 mln vs the $7.28 mln consensus.

• Record volume of more than 3,250 AlloMap diagnostic tests administered and processed, with a continued reimbursement of rate of 80%

Co reaffirms guidance for FY15, sees FY15 revs of $28-30 mln vs. $29.60 mln Capital IQ Consensus Estimate.

4:13 pm Cara Therapeutics misses by $0.02, beats on revs (CARA) : Reports Q2 (Jun) loss of $0.25 per share, $0.02 worse than the Capital IQ Consensus Estimate of ($0.23); revenues fell 9.0% year/year to $0.87 mln vs the $0.76 mln consensus.

Expected Upcoming Milestones 

• Initiate I.V. CR845 adaptive pivotal trial in abdominal surgery in 3Q'15.
• Initiate Phase 2a trial for Oral CR845 in OA (osteoarthritis) patients in 3Q'15. 
• Report top-line data from Phase 2a trial of Oral CR845 by the end of 2015. 
• Hold meeting with FDA to inform Registration program for I.V. CR845 in uremic pruritus before the end of 2015.
• Application for orphan drug status and breakthrough designation for I.V. CR845 in uremic pruritus in 4Q'15.
  

4:12 pm American Midstream Partners announces ArcLight Capital Partners will drop down 25% of its 51.7% controlling interest in Delta House (AMID) : The co announced the intention of an affiliate of ArcLight Capital Partners, which controls the general partner of the Partnership, to drop down 25 percent of ArcLight's 51.7 percent controlling interest in Delta House, a fee-based, semi-submersible floating production system and associated oil and gas export pipelines in the deepwater Gulf of Mexico.

• American Midstream and ArcLight anticipate closing the drop-down transaction before year-end 2015 at a purchase price of $162 million. ArcLight's remaining interest in Delta House is potentially available for future drop-down transactions depending on market conditions and other factors. Total acquisition consideration for the transaction equates to an Adjusted EBITDA multiple of approximately five times for the next twelve months and full-year 2016. At its current unit price, the Partnership anticipates financing the transaction without accessing the public equity markets. 
• Delta House is operated by LLOG Exploration Offshore, L.L.C. and is located in the Mississippi Canyon region of the deepwater Gulf of Mexico, with nameplate processing capacity of 80,000 barrels of oil per day (Bbl/d) and 200 million cubic feet of gas per day (MMcf/d), and peak processing capacity of 100,000 Bbl/d and 240 MMcf/d, respectively. Cash flows for Delta House are supported by a 100 percent, volumetric-tiered fee-based tariff structure with ship-or-pay components and life-of-lease dedications.
  

4:11 pm Alimera Sciences misses by $0.03, misses on revs (ALIM) : Reports Q2 (Jun) loss of $0.25 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus Estimate of ($0.22); revenues rose 163.7% year/year to $5.78 mln vs the $6.49 mln consensus.

• "The second quarter was our first full quarter of ILUVIEN sales in the U.S., and we are very pleased with the results. In particular, ILUVIEN generated $3.8 million in sales in the U.S., which accounted for approximately 66% of our total revenue for the quarter with downstream demand from physicians increasing 180% from 1Q15."
• "While it is encouraging to see such initial strength in uptake, we believe we are just scratching the surface of this market opportunity. We expect to see continuing increases as U.S. physicians experience similar patient outcomes as we have seen in Europe and as they begin receiving more insurance payments....We continue to see strength in the United Kingdom and our ongoing efforts to relaunch in Germany have also begun to show a positive impact."
  

4:11 pm Novavax announces positive top-line data from a Phase 2 clinical trial of its RSV F vaccine (NVAX) : The co. announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older). The RSV F Vaccine was well-tolerated and fulfilled the Company's expectations of the primary, secondary and exploratory objectives of the trial.

4:11 pm Grand Canyon Education beats by $0.02, reports revs in-line; guides Q3 EPS in-line, revs in-line; guides Q4 (Dec) EPS in-line, revs in-line; guides FY15 EPS in-line, revs in-line (LOPE) : Reports Q2 (Jun) earnings of $0.55 per share, $0.02 better than the Capital IQ Consensus Estimate of $0.53; revenues rose 10.2% year/year to $174.7 mln vs the $173.09 mln consensus. Co issues in-line guidance for Q3, sees EPS of approx $0.65, excluding non-recurring items, vs. $0.66 Capital IQ Consensus Estimate; sees Q3 revs of approx $191.8 mln vs. $194.00 mln Capital IQ Consensus Estimate. Co issues in-line guidance for Q4 (Dec), sees EPS of approx $0.78, excluding non-recurring items, vs. $0.78 Capital IQ Consensus Estimate; sees Q4 (Dec) revs of approx $211.9 mln vs. $212.43 mln Capital IQ Consensus Estimate. Co issues in-line guidance for FY15, sees EPS of approx $2.70, excluding non-recurring items, vs. $2.70 Capital IQ Consensus Estimate; sees FY15 revs of approx $772.6 mln vs. $773.66 mln Capital IQ Consensus Estimate.

4:10 pm Ntelos Holdings: Shenandoah Telecom enters into a definitive agreement to acquire NTELOS Holdings Corp (NTLS) for $9.25/share in cash (NTLS) : Co announced that it has entered into a definitive agreement to acquire NTELOS Holdings Corp. (NTLS) for $9.25 per share in cash for a total equity value of ~$208 million, after including shares expected to vest on change of control.

• Under the terms of the agreement, Shentel will acquire all of nTelos' stock and operations including wireless network assets, retail stores and approximately 298,000 retail subscribers in the nTelos Western Markets. Shentel will complete nTelos' plans to close down its Eastern markets and at closing Shentel will pay off nTelos' outstanding debt which was $523 million at June 30, 2015. 
• Concurrently with the signing of the agreement with nTelos, Shentel and Sprint Corporation (S) entered into a series of agreements, including an Addendum to the Shentel Affiliate Agreement and related agreements, whereby Shentel and Sprint will, among other things, exchange certain assets in the nTelos Western Area. 
• Sprint will receive certain spectrum assets of nTelos, and has agreed to reduce the retained revenues that would otherwise be due to Sprint under the Affiliate Agreement by $252 million over an expected period of five to six years. After taking into account the payments from Sprint for the exchange of certain assets, Shentel's net consideration of the nTelos acquisition will be $330 million. 
• Upon close of the transaction, Shentel's wireless segment will continue to operate as a Sprint Affiliate and is expected to serve a licensed market area with a total population ("POP") of 5.4 million, a network that covers 4.3 million POPs and total subscribers of over 1 million. 
• Shentel will finance the nTelos acquisition and network upgrade with $960 million in credit facilities (including term loans totaling $885 million and a revolver of $75 million) from a syndicate of lenders
  

4:09 pm ICU Medical beats by $0.41, beats on revs; raises FY15 EPS and revenue guidance, above consensus (ICUI) : Reports Q2 (Jun) earnings of $0.97 per share, excluding non-recurring items, $0.41 better than the Capital IQ Consensus Estimate of $0.56; revenues rose 6.5% year/year to $83.7 mln vs the $78.89 mln consensus. "Our second quarter results were above our expectations as we achieved growth in both our direct and OEM channels."

• Co raises guidance for FY15, sees EPS of $3.49-3.69, excluding non-recurring items, vs. $2.53 Capital IQ Consensus Estimate, up from $2.70-2.80.
• Co raises FY15 revs guidance to $325-330 mln vs. $318.92 mln Capital IQ Consensus Estimate, up from $312-317 mln.
  

4:08 pm Kraft Heinz beats by $0.08, misses on revs; reaffirms cost savings target of $1.5 bln by 2017 (KHC) : Reports Q2 (Jun) earnings of $0.92 per share, $0.08 better than the Capital IQ Consensus Estimate of $0.84; revenues fell 4.9% year/year to $4.51 bln vs the $4.7 bln consensus, including a negative 1.4 percent impact from currency. Kraft Organic Net Revenues decreased 3.3 percent driven by a 2.6 percent decline from volume/mix and a 0.7 percent decline from lower net pricing.

• Volume/mix included an approximate one percentage point negative impact from the timing of Easter-related shipments and an approximate one percentage point negative impact from lower ready-to-drink beverage sales resulting from decreased promotional activity versus the prior year quarter as well as retail inventory shifts this year.
• Lower net pricing reflected pricing actions in the Cheese and Foodservice businesses related to lower dairy costs that were partially offset by the carryover impact of price increases taken in prior quarters. 

Co remains confident in its ability to deliver against its initial financial expectations for the merger of Kraft and Heinz, including its expectation to generate aggressive, run-rate cost savings of $1.5 billion by the end of 2017, inclusive of savings from productivity and cost savings initiatives contemplated prior to the merger.

4:08 pm magicJack VocalTec beats by $0.18, reports revs in-line (CALL) : Reports Q2 (Jun) earnings of $0.38 per share, excluding non-recurring items, $0.18 better than the Capital IQ Consensus Estimate of $0.20; revenues fell 13.8% year/year to $25.4 mln vs the $25.53 mln consensus.

4:08 pm Relypsa enters into an exclusive partnership with Vifor Fresenius Medical Care Renal Pharma to commercialize Patiromer for Oral Suspension (RLYP) : The co. and Vifor Fresenius Medical Care Renal Pharma Ltd. (:VFMCRP) announced they have entered into an exclusive partnership to commercialize Patiromer for Oral Suspension (Patiromer FOS), Relypsa's investigational medicine for the treatment of hyperkalemia. Relypsa will receive an upfront cash payment of $40 mln and will be eligible to receive payments of up to $125 mln upon achieving certain regulatory and sales based milestones. In addition, Relypsa will receive tiered double-digit royalties on net sales of Patiromer FOS in the licensed territories. VFMCRP will obtain an exclusive marketing right from Relypsa in worldwide territories except the United States and Japan, where Relypsa retains all commercial rights. Relypsa and VFMCRP will collaborate on ongoing development of Patiromer FOS, including submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (:EMA)

4:07 pm Vitae Pharmaceuticals initiates a Phase 1, multiple ascending dose clinical trial of VTP-43742 (VTAE) : Co announced that it has initiated a Phase 1 multiple ascending dose clinical trial of VTP-43742, its wholly owned and first-in-class ROR?t inhibitor product candidate for the treatment of autoimmune disorders, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and multiple sclerosis, as well as numerous orphan indications.

• Vitae plans to conduct this multiple ascending dose clinical trial in two populations. 
• This trial coincides with an ongoing Phase 1 single ascending dose study of VTP-43742, which Vitae initiated in June 2015 and for which results are expected in the second half of 2015.
  

4:07 pm Vipshop beats by $0.02, reports revs in-line; guides Q3 revs in-line (VIPS) : Reports Q2 (Jun) earnings of $0.14 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus Estimate of $0.12; revenues rose 77.6% year/year to $1.45 bln vs the $1.44 bln consensus.

• The number of active customers for the second quarter of 2015 increased by 47.2% to 14.2 million from 9.7 million in the prior year period. The number of total orders for the second quarter of 2015 increased by 55.2% to 44.9 million from 28.9 million in the prior year period.
  

Co issues in-line guidance for Q3, sees Q3 revs of RMB 9.1-9.3 bln (~$1.47-1.5 bln) vs. $1.5 bln Capital IQ Consensus Estimate.

4:07 pm Shake Shack beats by $0.06, beats on revs; raises FY15 revs and SSS outlook (SHAK) : Reports Q2 (Jun) earnings of $0.09 per share, $0.06 better than the Capital IQ Consensus Estimate of $0.03; revenues rose 75.9% year/year to $48.5 mln vs the $42.8 mln consensus. 

• Same Shak Sales 12.9%; Street expectations were in the range of 8-9%.
• Operating Profit 30.3%; Q1 25.7%.
• Domestic Co-Operated Avg Weekly Sales $102K; Q1 $89K.
• Food & Paper Costs 29.4%; Q1 30.5%.
• Labor & Related Costs 24.0%; Q1 25.2%

Co issues upside guidance for FY15, sees FY15 revs of $171-174 mln (Prior $161-165 mln) vs. $170.44 mln Capital IQ Consensus Estimate. 

• Increasing same-Shack sales growth to mid- to high-single digits (vs. low- to mid-single digits). 
• Increasing the total new domestic company-operated Shacks to be opened in 2015 to 12 (vs. 10).
• Additionally, the Company expects to open at least 12 new domestic company-operated Shacks in 2016 and beyond.
• Continuing to expect at least five international licensed Shacks to be opened under the Company's current license agreements in the U.K. and Middle East.
  

4:07 pm Papa Murphy's misses by $0.01, beats on revs (FRSH) : Reports Q2 (Jun) earnings of $0.09 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus Estimate of $0.10; revenues rose 33.3% year/year to $29.12 mln vs the $28.5 mln consensus.

• Domestic system comparable store sales increased +4.5%, including increases of +4.9% at company-owned stores and +4.5% at domestic franchisee-owned stores.
• "We are pleased with our second quarter results, which demonstrate the continued strength of our operating momentum. Driving this top and bottom line growth, was our 18th consecutive quarter of comparable store sales increases, the opening of 20 new Papa Murphy's locations system-wide, including six Company-owned stores in the U.S., as well as our continued focus on execution and improving operations."
• "The consistency of our results adds to our confidence that we can more than triple our current store count...We continue to make progress on the roll out of POS and online ordering capabilities, which are now in approximately 1,100 and 750 stores, respectively, as we lay the foundation for precision marketing. We see enormous value in this digital strategy, which should yield significant sales growth and margin expansion in the years ahead...."
  

4:06 pm Regency Centers prices its public offering of $250 mln 3.90% unsecured notes due 2025 (REG) : The co. announced that its operating partnership, Regency Centers, L.P., priced a public offering of $250 mln 3.90% unsecured notes due 2025 (the "Notes"). The Notes are due November 1, 2025 and were priced at 99.264%. Interest on the notes is payable semiannually on May 1st and November 1st of each year, with the first payment on November 1, 2015. The net proceeds from the sale of the Notes will be used to pay amounts outstanding under the Company's line of credit.

4:06 pm CUI Global beats by $0.03, misses on revs (CUI) : Reports Q2 (Jun) net of breakeven, $0.03 better than the Capital IQ Consensus Estimate of ($0.03); revenues rose 19.8% year/year to $23 mln vs the $23.4 mln consensus.

• Quarterly gross profit margin was 36%, as compared to 40%, while year to date gross profit margin was 37% as compared to 41%.
  
  
• Power and Electro-Mechanical segment unaudited backlog of $23.7 million as of June 30, 2015. Gas segment unaudited backlog of $17.2 million as of June 30, 2015.
  

4:06 pm Relypsa enters into a two-year detailing agreement with Sanofi (SNY) for Patiromer (RLYP) : The co. announced it has entered a two-year detailing agreement with Sanofi for Patiromer for Oral Suspension (Patiromer FOS). Relypsa intends to commercialize Patiromer FOS, if approved, with its own dedicated U.S.-based commercial team and specialty sales force of approximately 120 sales representatives. Under the terms of the agreement, Sanofi's nephrology sales force will complement Relypsa's efforts by detailing Patiromer FOS in the United States for a two-year period. During the term of the agreement, Sanofi will be paid a service fee and is also eligible to receive incentive payments.

4:06 pm Closing Market Summary: Cyclical Sectors Lead Stocks Higher (:WRAPX) : The stock market began the trading week on a sharply higher note with the S&P 500 spiking 1.3% while the Dow (+1.4%) and Nasdaq (+1.2%) bookended the benchmark index.

Equity indices surged out of the gate after the overnight session featured a 4.9% spike in China's Shanghai Composite after below-consensus trade data from China was viewed as an argument in favor of more policy easing. The overnight strength carried over to the European session as regional indices rallied amid reports suggesting Greek officials and eurozone negotiators are nearing a final agreement on a third bailout package for Greece.

Once the opening bell rang on Wall Street, U.S. stocks perked up with the S&P 500 charging above its 50-day (2,096) and 100-day (2,098) moving averages. The benchmark index overtook both those levels during the opening hour, and inched to new highs during afternoon action with nine sectors ending in the green.

Cyclical sectors paced the opening rally and they continued showing relative strength into the afternoon. The industrial sector (+1.9%) was the early leader, thanks to a 19.1% surge in Precision Castparts (PCP 230.93, +37.05) after the company agreed to be acquired by Berkshire Hathaway (BRK.B 143.39, -0.16) for $235/share.

Meanwhile, another cyclical sector-energy (+3.1%)-took the lead during late morning action thanks to an intraday spike in crude oil. The energy component jumped 2.5% to $44.95/bbl with the move partially supported by dollar weakness as the Dollar Index (97.17, -0.40) fell 0.4%.

Elsewhere among cyclical groups, the top-weighted technology sector (+1.6%) settled among the leaders with chipmakers showing notable strength. The PHLX Semiconductor Index soared 2.5% with all but one component ending in the green.

Moving to the countercyclical side, the telecom services sector (+1.8%) settled ahead of the broader market while consumer staples (+0.4%), health care (+0.8%), and utilities (-0.4%) underperformed.

The utilities sector struggled throughout the day as higher Treasury yields made rate-sensitive utility stocks less appealing. The 10-yr note settled just above its low with the benchmark yield higher by seven basis points at 2.24%.

Today's participation was roughly in-line with average as 800 million shares changed hands at the NYSE floor.

Investors did not receive any economic data today, but tomorrow, preliminary Q2 productivity (Briefing.com consensus 1.4%) and unit labor cost (consensus -0.1%) data will be released at 8:30 ET while June Wholesale Inventories will be reported at 10:00 ET.

• Nasdaq Composite +7.7% YTD 
• S&P 500 +2.2% YTD 
• Russell 2000 +1.4% YTD 
• Dow Jones Industrial Average -1.2% YTD

4:06 pm Installed Building Products acquires Eastern Contractor Services; expects $23 mln of added annualized revenue (IBP) : The co announced the acquisition of Eastern Contractor Services based in New Jersey and operating as Parker Insulation and Building Products in Nederland, Texas.

4:05 pm Cimpress acquires UK trade printer, Tradeprint; terms not disclosed (CMPR) :  

4:05 pm Entellus Medical Announces Exclusive Collaboration With Fiagon (ENTL) : The co. announced a collaboration with Fiagon NA Corporation, a manufacturer of the latest generation in innovative surgical navigation systems. The agreement enables Entellus to be the exclusive distributor of Fiagon Image Guidance Systems for ENT offices and ENT Ambulatory Surgery Centers in the United States

4:05 pm Insulet Company reiterates preliminary second quarter 2015 revenue results and revenue guidance for Q3 and FY15; anticipates that it will file its quarterly report on Form 10-Q for the period on or before Monday, August 17, 2015. (PODD) : On July 29, 2015 co provided prelim Q2 revs of $75.6 mln and guided for Q3 revs of $82-85 mln (vs current Capital IQ Consensus Estimate of $83.54 mln) and FY15 revs of $305-320 mln (vs current Capital IQ Consensus Estimate of $304.53 mln).

4:04 pm Galapagos NV announces that the selective JAK1 inhibitor filgotinib as once-daily monotherapy at week 24 showed further improvements in signs and symptoms of moderately to severe, active rheumatoid arthritis in the DARWIN 2 Phase 2B study (:GLPG) : Co announced that the selective JAK1 inhibitor filgotinib as once-daily monotherapy at week 24 showed further improvements in signs and symptoms of moderately to severe, active rheumatoid arthritis (:RA) in the DARWIN 2 Phase 2B study. Filgotinib was well tolerated in this study. Hemoglobin levels increased. These final 24-week study results are consistent with the efficacy and safety profile of filgotinib observed in prior clinical studies. With these final results, the data package for AbbVie is complete, which triggers the start of the licensing decision period.

4:04 pm Cooper acquires Reprogenetics for $46.5 mln; The transaction is valued at ~$46.5 million and is expected to be neutral to fiscal 2015 and 2016 earnings per share and accretive thereafter (COO) : Co announced that CooperSurgical, its women's health care unit, has acquired Reprogenetics, the largest genetics laboratory specializing in preimplantation genetic screening (:PGS) and preimplantation genetic diagnosis (PGD) used during the in-vitro fertilization (:IVF) process. The transaction is valued at approximately $46.5 mln and is expected to be neutral to fiscal 2015 and 2016 earnings per share and accretive thereafter, excluding one-time charges and deal-related amortization. As of July 31, 2015, Reprogenetics had trailing twelve month sales of approximately $20 million, and forecasted growth is expected to be in the low double digits in the coming years.

4:04 pm Kite Pharma misses by $0.01 (KITE) : Reports Q2 (Jun) loss of $0.26 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus Estimate of ($0.25); revenue rose to $4.4 mln vs $2.9 mln consensus, up from $0 in the prior year's quarter. 

• The increase was primarily comprised of the amortization of deferred revenue related to the $60.0 million upfront payment received from Amgen in the first quarter of 2015.
  

4:03 pm MRV Comms sells its network integration subsidiary Tecnonet S.p.A to Maticmind S.p.A. for $21.4 mln (MRVC) : Co entered into an agreement on August 7, 2015 to sell Tecnonet S.p.A., its Network Integration subsidiary based in Rome, Italy, to Maticmind S.p.A. based in Milan, Italy for total consideration of 19.7 mln or approximately $21.4 mln based on the current exchange rate of 1.09 USD/. The consideration includes a cash payment by Maticmind to MRV of 15.6 mln at closing plus a cash payment by Tecnonet to MRV of 4.1 mln prior to closing to repay an outstanding intercompany obligation. MRV is entitled to seek and procure third party debt financing for Tecnonet to provide the funds for this payment, and Maticmind is obligated to assume this debt at closing. Within 60 days of closing, the parties are required to make a post-closing adjustment based on changes in debt and cash of Tecnonet between June 30, 2015 and closing, as provided for in the purchase agreement. The transaction is subject to stockholder approval at a special meeting to be held as promptly as reasonable on or before November 30, 2015.

4:03 pm Ramco-Gershenson increases quarterly dividend to $0.21/share from $0.20/share (RPT) :  

4:02 pm Rackspace reports EPS in-line, revs in-line, guides for Q3 and Q4 (RAX) : Reports Q2 (Jun) earnings of $0.20 per share, in-line with the Capital IQ Consensus Estimate of $0.20; revenues rose 10.9% year/year to $489.4 mln vs the $490.53 mln consensus. For Q3, co expects revenue to grow between 2.0-3.5% on a constant currency basis and adjusted EBITDA margins to be between 33-34%. For Q4, co expects revenue to grow between 2.0-3.5%, on a constant currency basis. Co expects adjusted EBITDA margins to be between 33-34%. For the full year, co expects revenue to grow between 12-14%, on a constant-currency basis. Co expects adjusted EBITDA margins to be between 33-34%.

4:02 pm National General announces an offering of 10 mln shares of common stock, and subordinated notes due 2055 (NGHC) : Co announced it has commenced concurrent underwritten public offerings of 10,000,000 shares of its common stock and Subordinated Notes due 2055. Co has granted the underwriters in the common stock offering a 30-day option to purchase up to an additional 1,500,000 shares of the common stock and the underwriters in the Subordinated Notes offering a 30-day over-allotment option to purchase additional Subordinated Notes.

4:01 pm Post announces an offering of $600 mln in senior notes due 2024 and $600 mln in senior notes due 2025; also reports an offering of $275 mln in common stock (POST) : The co. announced it intends to commence a private offering of $600 mln in aggregate principal amount of senior notes due 2024 and $600 million in aggregate principal amount of senior notes due 2025 (collectively, the "Notes"). The Notes will be unsecured unsubordinated obligations of the co. and will be guaranteed by the co.'s domestic subsidiaries. Post also announced it intends to commence an underwritten public offering, subject to market and other conditions, of $275.0 million of its common stock. The co. expects to grant the underwriters for the common stock offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock issued.  The co. intends to use the net proceeds from the proposed offerings to repay a portion of its secured term loan outstanding under its credit agreement, to pay related fees and expenses and for general corporate purposes, which could include, among other things, financing potential future acquisition opportunities, working capital and capital expenditures

4:00 pm Portfolio Recovery Assoc. appoints Kevin Stevenson as President, effective immediately (PRAA) : Effective immediately, Kevin Stevenson, formerly executive vice president, chief financial and administrative officer, treasurer and assistant secretary, will assume the role of president, PRA Group, and will join the company's board of directors.

• In his new role as president, Stevenson will assume the additional responsibility of the operations in the Americas, with both the Core and Insolvency groups reporting to him. He will continue in his role as chief financial and administrative officer until a new chief financial officer is found. 
• At that time, Stevenson will also continue as chief administrative officer.